Navigation Links
Cowen Healthcare Royalty Partners and Cowen Group, Inc. Announce Closing of Fund
Date:7/21/2008

th over $500 million under management. The firm invests principally in commercial-stage biopharmaceutical and medical device companies through the purchase of royalty or Synthetic Royalty(SM) interests, debt and equity. CHRP's investment team has over 90 years of healthcare related experience including principal investing, structured finance, healthcare industry senior management, Wall Street research and consulting, scientific and clinical experience. For more information visit http://www.cowenroyalty.com.

Media Contacts:

For CHRP:

Kellie Walsh

914-315-6072

kwalsh@kwmcommunications.com

For Cowen Group, Inc.:

Jean Calleja

646-562-1888


'/>"/>
SOURCE Cowen Healthcare Royalty Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008
2. Cowen Group, Inc. Announces 2008 First Quarter Results
3. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
4. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
5. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
6. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
7. MannKind to Present at the Cowen and Company Healthcare Conference
8. Johnson & Johnson to Participate in the 28th Annual Cowen & Company Health Care Conference
9. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
10. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
11. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 1Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 2Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 3Tailor made HIV AIDS treatment closer to reality 62127 1Tailor made HIV AIDS treatment closer to reality 62127 2Its not just dirt 21 10899 1Its not just dirt 21 10899 2